Sign In  |  Register  |  About Santa Clara  |  Contact Us

Santa Clara, CA
September 01, 2020 1:39pm
7-Day Forecast | Traffic
  • Search Hotels in Santa Clara

  • ROOMS:

Dyadic International Inc. (DYAI): Bird Flu Vaccine Development Amid Rising Pandemic Concerns

Dyadic International Inc. (DYAI): Bird Flu Vaccine Development Amid Rising Pandemic Concerns

The coronavirus pandemic, a vivid memory for many, halted the world and reshaped lives. Despite a return to normalcy, the threat of pandemics persists, with the H5N1 avian flu (bird flu) emerging as a potential danger. Health experts caution that a bird flu outbreak could be 100 times more severe than COVID-19. 

Dyadic International Inc. (NASDAQ: DYAI), known for its protein development for animal and human vaccines and therapeutics, is at the forefront of this effort. Their proteins are used in diverse applications, including nutrition, food, and wellness. Promising data have emerged from their pre-clinical bird flu vaccine studies, Dyadic bird flu vaccine could be crucial in combating a potential outbreak in humans. Recently, the company’s COO Joe Hazelton Discussed the "Bird Flu" and Expansion into the “Future Of Foods” on “The Street Reports Podcast”  Listen to The Podcast Now!

In response to this looming threat, the U.S. government has initiated discussions with Moderna (NASDAQ: MRNA) regarding an avian flu vaccine. Other companies, such as Pfizer (NYSE: PFE), Novavax (NASDAQ: NVAX), BioNTech (NASDAQ: BNTX), and Dyadic International Inc (NASDAQ: DYAI), may also be involved. 

Outbreaks naturally cause concern, prompting companies to find solutions. On May 22, Australia reported its first human bird flu case, followed by a second U.S. case involving a Michigan farm worker. This surge in cases has spurred the U.S. government to engage with Moderna for vaccine development. Dyadic International Inc (NASDAQ: DYAI) is a key player to watch, given its proactive approach and promising bird flu vaccine candidate developed in collaboration with ViroVax. 

Dyadic's H5 bird flu vaccine candidate, offers significant advantages in terms of lower costs and accelerated manufacturing. Pre-clinical animal data ViroVax showed high neutralizing antibodies for three distinct H5 viruses, indicating its potential use in both cattle and humans. Scalability and flexibility are strengths of the Dyadic vaccine candidate, positioning it as a dynamic solution for a global health crisis. 

The C1 production platform used by Dyadic is sustainable and cost-effective compared to MRNA and other vaccine production processes. This makes Dyadic International a crucial player in addressing the bird flu threat and ensuring preparedness for a potential outbreak. Recently, the company’s COO Joe Hazelton Discussed Expansion into Food and Beverage and the “Future Of Foods” on “The Street Reports Podcast” Listen to The Podcast Now!


Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content."TSR" is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. "TSR" authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. "TSR" has not been compensated to produce content related to "Any Companies" appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.

Media Contact
Company Name: The Street Reports
Contact Person: Editor
Email: Send Email
Country: United States

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Copyright © 2010-2020 & California Media Partners, LLC. All rights reserved.